Kleniewski J
Thromb Haemost. 1979 Oct 31;42(3):1046-55.
High molecular weight kininogen (HMW-kininogen) concentration was measured in the plasma of healthy blood donors, patients with haemophilia A, idiopathic thrombocytopoenic purpura, deep vein thrombosis treated with oral anticoagulants and patients treated with streptokinase (SK). The concentration of HMW-kininogen in the plasma of healthy subjects was 92 +/- 15 micrograms/ml. The values obtained in patients' plasma were not different statistically. In the plasma of patients treated with repeated infusion of SK, a significant increase of HMW-kininogen antigen activity was noted after each injection of the drug. Similar results were obtained when SK was added to plasma "in vitro" or when a purified preparation of HMW-kininogen was treated with plasmin. These and additional data obtained suggest that plasmin uncovers in the HMW-kininogen molecule a new antigenic site(s) common to HMW-kininogen and low molecular weight kininogen and new antigenic site(s) specific only for HMW-kininogen.
在健康献血者、甲型血友病患者、特发性血小板减少性紫癜患者、接受口服抗凝剂治疗的深静脉血栓形成患者以及接受链激酶(SK)治疗的患者的血浆中测量了高分子量激肽原(HMW - 激肽原)浓度。健康受试者血浆中HMW - 激肽原的浓度为92±15微克/毫升。在患者血浆中获得的值在统计学上没有差异。在接受重复输注SK治疗的患者血浆中,每次注射该药物后,HMW - 激肽原抗原活性均显著增加。当在“体外”将SK添加到血浆中或用纤溶酶处理HMW - 激肽原的纯化制剂时,也获得了类似的结果。这些以及其他获得的数据表明,纤溶酶在HMW - 激肽原分子中揭示了一个HMW - 激肽原和低分子量激肽原共有的新抗原位点以及仅对HMW - 激肽原特异的新抗原位点。